Axogen Inc Stock
Price
Target price
€41.30
€41.30
-3.320%
-1.42
-3.320%
-
13.08.26 / Stuttgart Stock Exchange
WKN: A1JMHK / Name: AxoGen / Stock / Healthcare Equipment & Supplies / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Axogen Inc Stock
Heavy losses for Axogen Inc today as the stock fell by -€1.420 (-3.320%).
Pros and Cons of Axogen Inc in the next few years
Pros
?
S********** s********
?
B****
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
M***** P*******
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Axogen Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Axogen Inc | -3.320% | 9.930% | 23.864% | 254.250% | 51.821% | 672.909% | 208.043% |
| Fluidigm Corp. | -4.410% | -0.730% | -8.725% | -38.739% | -35.849% | -73.438% | -87.699% |
| Accuray Inc. | -1.900% | 2.759% | 15.834% | -80.646% | -64.117% | -91.465% | -92.855% |
| Pacific Biosciences of California Inc. | 2.500% | -0.890% | -23.715% | -9.485% | -32.589% | -90.765% | -95.992% |
Comments
News
AxoGen Q2 Earnings Call Highlights
Key Points
- Interested in AxoGen, Inc.? Here are five stocks we like better.
- Strong revenue growth: AxoGen’s second-quarter revenue rose 23.1% year over year to $69.7 million, driven largely by
AxoGen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather Steam
AxoGen (NASDAQ:AXGN) President and CEO Michael Dale said the company’s growth strategy remains centered on developing the market for peripheral nerve repair, while recent reimbursement wins are
This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth
DAFNA Capital Management cut its holding in Axogen (NASDAQ:AXGN) by 265,456 shares in the fourth quarter, an estimated $6.53 million trade based on quarterly average pricing, according to a February
